NCT07701343 tACS for Working Memory in Schizophrenia
| NCT ID | NCT07701343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central South University |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-07-06 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-07-06 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, single-blind, sham-controlled crossover trial enrolling 30 schizophrenia patients, each receiving one active and one sham tACS session (7-day washout), targeting P3/P4 at individual alpha frequency (2mA, 30min) during a working memory task, with accuracy and reaction time as primary outcomes, alongside EEG and neurophysiological measures, to test the efficacy and mechanisms of individualized alpha-tACS on working memory.
Eligibility Criteria
Inclusion Criteria: * Aged 18-50 years, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5). * Spatial span T-score \<40 on the MATRICS Consensus Cognitive Battery (MCCB). * Taking 1-2 antipsychotic medications, with stable dosage for at least 1 week prior to enrollment. No use of mood stabilizers, antidepressants, or excessive benzodiazepines (lorazepam equivalent \>2 mg/day). The type and dosage of antipsychotic medications remain unchanged during the treatment period. * Impaired functioning in daily activities. * Willing to participate in this study and provide written informed consent. Exclusion Criteria: * Previously diagnosed with or comorbid any other DSM-5 mental disorder besides schizophrenia. * Presence of significant mood symptoms or substance use disorder (other than caffeine and/or tobacco). * Presence of any contraindication to transcranial alternating current stimulation (tACS). * Received other forms of electrical or magnetic stimulation therapy within 1 month prior to enrollment. * History or current presence of any major physical illness, neurological disorder, or traumatic brain injury that may affect brain structure or function. * Pregnant or breastfeeding women, or women planning to become pregnant during the study period.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07701343 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07701343 currently recruiting?
Yes, NCT07701343 is actively recruiting participants. Contact the research team at wurenrong@csu.edu.cn for enrollment information.
Where is the NCT07701343 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT07701343 clinical trial?
NCT07701343 is sponsored by Central South University. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.